Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection.
about
Complexation of clofazimine by macrocyclic cucurbit[7]uril reduced its cardiotoxicity without affecting the antimycobacterial efficacy.Cyclosporine a-nanosuspension: formulation, characterization and in vivo comparison with a marketed formulation.Sustained-release progesterone nanosuspension following intramuscular injection in ovariectomized ratsClofazimine: current status and future prospects.Formulation and pharmacokinetic evaluation of a paclitaxel nanosuspension for intravenous delivery.Nanosuspension: An approach to enhance solubility of drugsNanosuspensions: a promising drug delivery strategy.The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis.Drug delivery systems: An updated reviewIn vivo biodistribution, biocompatibility, and efficacy of sorafenib-loaded lipid-based nanosuspensions evaluated experimentally in cancerDevelopment and evaluation of transferrin-stabilized paclitaxel nanocrystal formulation.Nanotechnology-Based Approach in Tuberculosis Treatment.Novel technologies: A weapon against tuberculosis.Effect of drug physico-chemical properties on the efficiency of top-down process and characterization of nanosuspension.A recent trend of drug-nanoparticles in suspension for the application in drug delivery.Arsthinol nanosuspensions: pharmacokinetics and anti-leukaemic activity on NB4 promyelocytic leukaemia cells.Understanding the structure and stability of paclitaxel nanocrystalsPreparation, characterization, pharmacokinetics, and tissue distribution of curcumin nanosuspension with TPGS as stabilizer.Comparison of nanomilling and coprecipitation on the enhancement of in vitro dissolution rate of poorly water-soluble model drug aripiprazole.Pharmacokinetic evaluation of a 1,3-dicyclohexylurea nanosuspension formulation to support early efficacy assessment.Distribution of an intravenous injectable nimodipine nanosuspension in mice.Preparation and characterization of an oridonin nanosuspension for solubility and dissolution velocity enhancement.A formulation comparison between micro- and nanosuspensions: the importance of particle size for absorption of a model compound, following repeated oral administration to rats during early development.Overcoming clofazimine intrinsic toxicity: statistical modelling and characterization of solid lipid nanoparticles.Preparation and in-vitro/in-vivo characterization of trans-resveratrol nanocrystals for oral administration.Advances in nanotechnology-based carrier systems for targeted delivery of bioactive drug molecules with special emphasis on immunotherapy in drug resistant tuberculosis - a critical review.Nano-engineering of liposomes using a supercritical CO2 mediated gas anti-solvent methodIncreasing Possibilities of NanosuspensionNanosuspension: An Emerging Trend for Bioavailability Enhancement of EtodolacNanosuspension Technologies for Delivery of Poorly Soluble Drugs
P2860
Q31116166-C22D3C1B-27CA-484F-AF31-2E327FA5F02BQ34409932-B8772E27-5D5C-4C3C-8AC7-BD0BC9F94E95Q34440041-20CEA242-706A-4075-8CCD-76FD9CA8177DQ34633213-CE774430-29DC-448F-A228-AC0351339526Q35122772-5812B64E-9583-4E81-9E2D-8C2A0471F910Q35554511-18EC8B03-1689-495E-96CE-AB2365C6E575Q35826447-61FCB85D-0A7F-424F-BBD1-A3A06F0D6E7FQ36252799-22DE2231-DC23-42E1-8EED-38D545CCFA8CQ36300205-ACF0748E-F46A-4A96-B1E7-1E82087B6CC7Q36951503-E71BF2F6-A976-418C-BBF1-13CC887FD30DQ37619232-F5246A74-861F-4765-983F-3294FDE5BAEBQ37624974-B18128A7-D68C-40B6-931B-21084EC0D2FDQ37824425-241631CF-3150-445D-A988-B86C51BA75B1Q38534116-BF34DF9F-42AC-4198-A9B8-FF8091841300Q38985268-BF1A01E7-FCC7-40A2-B362-0E9F86192F50Q39789952-0DDA3EC2-4728-415F-A05C-F42D5316477DQ41884506-088B14C7-280C-4146-90A0-126AECCB8C20Q43025626-A364BB2C-C922-4B2C-A825-E385137659E8Q44639623-86F72C27-13D3-4FF3-BFD2-3E1ADCE2F9A2Q46125868-5DA2813C-34CD-4F23-84A7-1CB47692DD0CQ46418387-A4DA2E56-8A9C-40CC-AEB9-103E00D29AB1Q46837639-6DF1C4B7-45A1-467F-9E7E-5AFBFBA5DC3EQ47422612-879B3951-66A8-492A-855A-CB9BC31243C4Q50048230-DF424E97-8B82-492A-9ED1-C0D31DECB9D3Q52790753-2C982C04-2259-42C9-ADDD-4A9435897FE1Q53379436-6FEADEC4-71F6-4C3E-803F-17E52339A84AQ58826618-BA5AEC36-3BCF-4C8B-B8E0-2F20D1536A71Q59019148-022DF3CA-1CD5-481E-88ED-74CCB3DE5E55Q59110992-C03A429E-C06E-4403-AA88-ED1350875705Q59113220-42445D1D-0F73-4A76-B97B-B67FEB0A829B
P2860
Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Preparation of a clofazimine n ...... Mycobacterium avium infection.
@ast
Preparation of a clofazimine n ...... Mycobacterium avium infection.
@en
type
label
Preparation of a clofazimine n ...... Mycobacterium avium infection.
@ast
Preparation of a clofazimine n ...... Mycobacterium avium infection.
@en
prefLabel
Preparation of a clofazimine n ...... Mycobacterium avium infection.
@ast
Preparation of a clofazimine n ...... Mycobacterium avium infection.
@en
P2093
P356
P1476
Preparation of a clofazimine n ...... Mycobacterium avium infection.
@en
P2093
Diederichs JE
P356
10.1093/JAC/45.1.77
P407
P577
2000-01-01T00:00:00Z